Strides Arcolab receives USFDA approval for Clindamycin Injection

03 Oct 2011 Evaluate

Strides Arcolab has received US FDA approval for Clindamycin Injection, USP, an antibiotic used to treat bacterial infections. Clindamycin Injection will be available in three single dose vial sizes and in pharmacy bulk packaging. As with all products in Strides- Sagent JV, Clindamycin features the prevent IV measures packaging and labeling designed to aid in reduction of the medication errors.

According to the IMS, the 2011 US market for injectable Clindamycin approximates to $65 million. The product is expected to be launched in early 2012. Clindamycin is the twelfth product approved under the Sagent-Strides partnership. The company is developing and supplying more than 25 injectables products for the USA market which will be marketed by Sagent.

Strides Pharma Scien Share Price

859.00 22.45 (2.68%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.